Mississauga, ON -- (SBWIRE) -- 04/04/2013 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Cellular Biomedicine Group Looking to Make its Mark in Stem Cells with Start of Second Clinical Trial.”

Article Excerpt:

For long-term biotech investors, it’s hard to overlook the dynamic shift that has been gaining traction in recent years to not necessarily shift away from small molecule therapies, but certainly put more emphasis on other areas as well, such as immunology and stem cell therapies. Stem cells, whether derived from the patient, called autologous, or from a donor, called allogeneic, have been gaining a lot more attention as the industry seems to have past its tipping point with several companies now in mid and late-stage clinical trials to validate the therapeutic benefit and safety of their processes.

Looking to build its footprint in the stem cell business is Cellular Biomedicine Group (OTCQB:CBMG), a Palo Alto, California-based developmental biotech taking its technology to the clinic now. The company, known as EastBridge Investment Group Corp until a merger with the now namesake in February followed by name and ticker change on March 5th, is focused on developing new therapies using progenitor cell and dendritic cell technologies.

The full version of this article can be found at:

http://www.allpennystocks.com/aps_us/special-reports/345/cellular-biomedicine-group-looking-to-make-its-mark-in-stem-cells-with-start-of-second-clinical-trial.htm

About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.

AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.

Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.

Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.